Abstract:Inducible nitric oxide synthase (iNOS) metabolizes L-arginine to produce NO that was originally identified in myeloid cells as a host defense mechanism against pathogens. Recent studies, however, have revealed that iNOS is often induced in both tumor and myeloid cells in the tumor microenvironment. More intriguingly, compelling experimental data have shown that iNOS promotes tumor development in certain cellular context and suppress tumor development under other cellular conditions. The molecular mechanisms underlying this contrasting function of iNOS is unknown. Because iNOS is often induced by inflammatory signals, it is therefore likely that the opposite functions of iNOS might be controlled by the inflammatory signaling pathways. We show here that proinflammatory IFN-γ and NF-κB signals synergistically induce iNOS expression in human colon cancer cells. We further demonstrated that NF-κB directly binds to the NOS2 promoter to regulate iNOS expression. Although the IFN-γ signaling pathway or the NF-κB signaling pathway alone is insufficient to induce iNOS expression in myeloid cells, IFN-γ and NF-κB synergistically induce iNOS expression in myeloid cells. Furthermore, we determined that IFN-γ up-regulates IRF8 expression to augment NF-κB induction of iNOS expression. More interestingly, we observed that the p65/p65 and p50/p50 homodimers, not the canonical p65/p50 heterodimer, directly binds to the nos2 promoter to regulate iNOS expression in myeloid cells. Our results thus determine that the IFN-γ-induced IRF8 acts in concert with the NF-κB p65/p65 and p50/p50 homodimers to regulate iNOS expression. Citation Format: Priscilla Simon, Sarah Sharman, Chunwan Lu, Dafeng Yang, Amy Paschall, Kebin Liu. The NF-κB p65 and p50 homodimer cooperate with pSTAT1 to synergistically activate iNOS transcription. [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2015;3(10 Suppl):Abstract nr B86.

NIP45 controls the magnitude of the type 2 T helper cell response

Tumor necrosis factor receptor-associated factor (TRAF)2 represses the T helper cell type 2 response through interaction with NFAT-interacting protein (NIP45)

NF-AT-Driven Interleukin-4 Transcription Potentiated by NIP45

Noncanonical NF-κB Pathway Controls the Production of Type I Interferons in Antiviral Innate Immunity

Neuroprotective protein ADNP-dependent histone remodeling complex promotes T helper 2 immune cell differentiation

Targeted deletion of NFAT-Interacting-Protein-(NIP) 45 resolves experimental asthma by inhibiting Innate Lymphoid Cells group 2 (ILC2)

Essential Role of NPAT in Regulating T Cell Development and Function

Negative Regulation of NIP45 Function by Peptidylarginine Deminase 4 (87.28)

Ncf1 provides a reactive oxygen species-independent negative feedback regulation of TLR9-induced IL-12p70 in murine dendritic cells.

TRAF1 regulates Th2 differentiation, allergic inflammation and nuclear localization of the Th2 transcription factor, NIP45

Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation

NLRP10 Enhances CD4+ T-Cell-Mediated IFNγ Response via Regulation of Dendritic Cell-Derived IL-12 Release

CNBP controls IL-12 gene transcription and Th1 immunity

NFATc1/αA and Blimp-1 Support the Follicular and Effector Phenotype of Tregs

IFN-γ suppresses permissive chromatin remodeling in the regulatory region of the Il4 gene.

Beyond Innate Immunity: Defining a Role for Interferon Regulatory Factor 3 in CD4+ T Cell Responses

NFATC3 promotes IRF7 transcriptional activity in plasmacy--toid dendritic cells.

NFAT1 and NFκB regulates expression of the common γ-chain cytokine receptor in activated T cells

Abstract B86: the NF-κB P65 and P50 Homodimer Cooperate with Pstat1 to Synergistically Activate Inos Transcription

The transcription factor lymphoid enhancer factor 1 controls invariant natural killer T cell expansion and Th2-type effector differentiation.